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   Over 800 000 people die due to suicide every year, which is the second leading 
cause of death worldwide (behind road traffic injuries) in 15-29-year-olds. For each 
adult who dies of suicide, as many as 20 others will attempt suicide [1].  Reduction of 
this death toll is key challenge and a comprehensive suicide prevention strategy 
should involve not only the health sector but also education, employment, social 
welfare and others stakeholders [1]. However, mood disorders are common disorders 
with an elevated risk of early death from suicide and mood disorder-related suicide 
should be a particular focus of concern.  The role of treatment (including medication) 
in suicide prevention is an important and often neglected topic. However, medicines 
which have proven good evidence for a suicide prevention effect are rare. Lithium 
was eventually fully accepted as a treatment for patients with psychiatric disorders 
some time after John Cade’s initial report in 1949.  After more than six decades of 
study, the efficacy of lithium as a treatment for mood disorders (both bipolar and 
unipolar), as shown in meta-analyses of clinical trials, is robust and these analyses 
also show clear effects of lithium in reducing suicide (both attempts and completed 
suicide). Cipriani et al [2] recently reported that compared to placebo, lithium 
treatment reduces mortality and suicide by more than 60% in patients with major 
depression or bipolar disorder (BD). Notably, other mood stabilizers, such as 
valproate and other anticonvulsants, have only weak effects on suicide compared 
with lithium [2]. Lithium, as well as being available as a medicine, is an element 
present in trace amounts to a variable degree in the environment.  Multiple studies 
have suggested that environmental lithium concentrations are negatively associated 
with reduced suicide rates since the first paper was published in 1990 [3]. Clinical and 
epidemiological studies also suggest that the antisuicidal effects of lithium may be 
greater in males than females [4, 5].  
   Evidence from patients with other mental disorders, behavioural disturbances and 
emotionally unstable personality disorders suggest that the antisuicidal effect of 
lithium is not simply a by product of its mood stabilising properties.  
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   Lithium’s antisuicidal effect is paralleled by an anti-aggressive effect, both of 
which may be mediated by effects on serotoninergic neurotransmission. Impulsivity 
and aggression have been associated with death by suicide and are among the most 
frequently implicated risk factors for engaging in suicide behaviour [6].  Higher levels 
of lithium in the drinking water may therefore decrease suicide rates by reducing 
impulsivity and aggression [7]. Though lithium salts have adverse effects, especially 
to kidney and thyroid function, these can be mitigated by careful monitoring [8]. One 
further problem with lithium treatment is that abrupt discontinuation is associated 
with increased mania and suicidal behaviour [9]. Assurance of good compliance is 
therefore essential. Improvement of clinical practice might be facilitated by 
education of both clinicians and patients about lithium’s benefits and harms. 
Improved monitoring reduces adverse long-term effects, and education about 
lithium is included in psychoeducational treatment strategies [10].  
   The association of increased levels of environmental lithium with reduced rates of 
completed suicide raises the hypothesis that a prescription at low or very low doses 
of lithium may provide well-tolerated, effective prevention of suicide in populations 
with high suicide risk, including patients with mood disorders. Potentially, 
psychiatrists may separate the mood stabilization effect and antisuicidal effect of 
lithium treatment as different dosages are needed.  However, the clinical trials which 
would be required to verify the benefits of this approach would be expensive, 
challenging and would require a major investment in research in this area.  
  Suicide is a major public health problem worldwide and lithium is one of the few 
interventions which have been shown convincingly to reduce suicide rates when 
used to treat mood disorders.  This is very important and strengthens the case for 
using lithium in appropriate clinical populations.  The recent findings that greater 
environmental lithium levels reduce suicide rates at a population level are 
intriguing.  Future research should focus on understanding the neural mechanism of 
this effect and whether this phenomenon may inform future public health strategies. 
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